In ES-SCLC, studies have shown that PD-1/PD-L1 inhibitors combined with chemotherapy are safer and more effective than chemotherapy alone, whereas PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors did not improve the efficacy (55). The gene discussed is CTLA4; the disease is small cell lung carcinoma.